Followers
68
Board Type
Free
Posts Today
0
Created
10/11/2012
Posts Last 30 Days
2
Posters
220
Moderators midastouch017

Can-Fite BioPharma (TASE:CFBI; NYSE MKT:CANF) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and liver diseases.

The company platform technology utilizes the Gi protein associated A3 adenosine receptor (A3AR) as a therapeutic target. A3AR is highly expressed in inflammatory and cancer cells where low expression is found in normal cells, suggesting that the receptor could be a unique target for pharmacological intervention. The company compounds bind with nM affinity to the A3AR and initiate de-regulation of the NF-kB and the Wnt signal transduction pathways resulting in anti-inflammatory and anti-cancer effects

 
 

The company pipeline drugs are synthetic, highly specific agonists and allosteric modulators targeting the A3AR. All drugs are orally bioavailable with an excellent safety profile. Piclidenoson (CF101), Can-Fite`s lead drug candidate, is an oral drug that has been successfully tested in animal models and is currently in Phase III clinical studies for the treatment of Rheumatoid Arthritis (RA) and Psoriasis. All human clinical studies have demonstrated this drug to have an excellent safety profile. In two Phase II studies where Piclidenoson has been given as a standalone drug, data indicated that it acted as a disease modifying anti-inflammatory drug in RA patients. The Phase II and the Phase II/III clinical studies in Psoriasis showed clinical activity and safety of the drug. Namodenoson (CF102), Can-Fite`s second drug candidate, is an oral drug currently being developed for the treatment of Liver Diseases including hepatocellular carcinoma and non-alcoholic steatohepatitis (NASH). CF602 an allosteric modulator at the A3AR which has shown proof of concept in pre-clinical pharmacology studies and is earmarked for the treatment of sexual dysfunction. Can-Fite has a wealth of clinical experience which includes over 1200 patients who have participated in clinical trials conducted by the company.

Can-Fite has licensed Piclidenoson for the treatment of autoimmune diseases to Cipher Pharmaceuticals in Canada, to Gebro Pharma GmbH in Spain, Switzerland & Austria,  for RA to Kwang Dong in Korea and to CMS for RA and Psoriasis in China, Taiwan, Hong Kong, Macao.

Can-Fite has licensed Namodenoson for the treatment of Liver Cancer and NASH to Chong Kun Dang Pharmaceut in Korea and to CMS in China.

Can-Fite is collaborating with leading researchers from the US NIH and the Leiden University in the Netherlands.

 

Israeli Office

10 Bareket Street
Kiryat Matalon
P.O. Box 7537
Petah-Tikva 49170
ISRAEL (Directions)

Tel: +972-3-9241114
Fax: +972-3-9249378

General email:
info@canfite.co.il

 

Investor Relations
(800)716-4880
info@canfite.co.il 


 

USA Office

255 Bear Hill Road, Suite 2200
Waltham
MA 02451
USA

Tel: +972-3-9241114
Fax: +972-3-9249378

http://www.canfite.com/

 

PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
#1809
Can-Fite Issues Letter to Shareholders midastouch017 01/05/2022 01:20:20 PM
#1934
Can-Fite BioPharma Ltd. Interview to Air on Bloomberg midastouch017 09/23/2022 08:27:05 AM
#1933
Can-Fite: New Phase III Psoriasis Data Showing Superior midastouch017 09/12/2022 07:58:56 AM
#1932
Dawson James Sticks to Their Buy Rating for midastouch017 09/04/2022 08:56:56 AM
#1931
On August 29, 2022, Can-Fite BioPharma Ltd. (the midastouch017 08/30/2022 12:09:38 AM
#1930
Unfortunately so, but was clear from prior financial Spideyboy 08/29/2022 09:23:30 AM
#1929
If company fails I will consider it my midastouch017 08/25/2022 08:00:34 AM
#1928
Hi Spideyboy, midastouch017 08/25/2022 07:57:24 AM
#1927
Can-Fite Reports Second Quarter 2022 Financial Results & midastouch017 08/25/2022 07:50:01 AM
#1926
I, as well, have invested in this up Ortiz 08/23/2022 08:53:57 AM
#1925
Spideyboy, you wrapped it up realistically midastouch017 08/23/2022 08:43:01 AM
#1924
That would of course be something different entirely :) Spideyboy 08/23/2022 08:37:32 AM
#1923
Hi again Midas, Spideyboy 08/23/2022 08:34:52 AM
#1922
If only USA would replace Romania for midastouch017 08/23/2022 08:31:47 AM
#1921
Hi Midas, Spideyboy 08/23/2022 08:25:11 AM
#1920
Honestly speaking, i cannot decipher midastouch017 08/23/2022 08:09:50 AM
#1919
That’s Two drugs on phase-3 for a rather Ortiz 08/23/2022 08:06:19 AM
#1918
Hi Spideyboy: midastouch017 08/23/2022 07:54:42 AM
#1917
Can-Fite’s Drug Namodenoson Approved for Compassionate Use Treatment midastouch017 08/23/2022 07:40:36 AM
#1916
Late breaking news. Positive PR today. Moving in Ortiz 08/22/2022 02:16:12 PM
#1915
A very perplexing company indeed. midastouch017 08/22/2022 08:18:25 AM
#1914
Can-Fite Selected to Present the Positive Psoriasis Phase midastouch017 08/22/2022 08:12:36 AM
#1913
Can-Fite: Reports Progress in the Development of Piclidenoson midastouch017 08/17/2022 08:16:06 AM
#1912
A very nice surprise indeed. Sure am glad to midastouch017 07/11/2022 04:09:23 PM
#1911
Hopefully they’ll have a late reaction to the Ortiz 07/11/2022 02:36:48 PM
#1910
Not a too enthusiastic market reaction, midastouch017 07/11/2022 08:56:22 AM
#1909
Let’s see how the market reacts. Ortiz 07/11/2022 08:51:27 AM
#1908
The news couldnt even break past a $1.00. The Stock Reader 07/11/2022 08:50:22 AM
#1907
Can-Fite to Submit FDA & EMA Registration Plans midastouch017 07/11/2022 07:59:04 AM
#1906
Im done with them as soon as I The Stock Reader 06/30/2022 08:54:36 AM
#1905
No email reply , no tel reply, not midastouch017 06/30/2022 08:03:40 AM
#1904
No reaction from CANF ir, i will midastouch017 06/30/2022 01:15:55 AM
#1903
This company can never hold a gain. Ive The Stock Reader 06/29/2022 01:48:49 PM
#1902
Damage done already. A correction should be forthcoming. Ortiz 06/29/2022 11:20:16 AM
#1901
They used Business Wire (a Berkshire Hathaway company Spideyboy 06/29/2022 11:05:50 AM
#1900
I suppose we are all in agreement. A Ortiz 06/29/2022 10:56:53 AM
#1899
Indeed. With a large CORRECTION written at the beginning Spideyboy 06/29/2022 10:24:49 AM
#1898
Of course, but of course we would prefer midastouch017 06/29/2022 10:20:18 AM
#1897
Me2. if I get a reply, I’ll post. Ortiz 06/29/2022 10:03:22 AM
#1896
I guess they blew the PR then. Ortiz 06/29/2022 10:02:13 AM
#1895
Nope, not any biased press, was copy/paste from Spideyboy 06/29/2022 09:52:24 AM
#1894
I rushed an email to IR with exactly your midastouch017 06/29/2022 09:52:04 AM
#1893
Correct, primary endpoints met. Pivotal too. Maybe a Ortiz 06/29/2022 09:47:12 AM
#1892
Confused here. I think they wrote something incorrectly Spideyboy 06/29/2022 09:41:22 AM
#1891
The global psoriasis treatment market is projected to Ortiz 06/29/2022 09:40:57 AM
#1890
I hope so. The market is in a Ortiz 06/29/2022 09:16:14 AM
#1889
Correction, “piclidenoson” I wonder what the brand name might be! IMO Ortiz 06/29/2022 09:11:36 AM
#1888
On the other hand CANF s/p is so midastouch017 06/29/2022 09:09:49 AM
#1887
Just throwing it out there,, superiority to Otezla Ortiz 06/29/2022 09:08:21 AM
#1886
You are right. Let’s see how the big Ortiz 06/29/2022 08:56:48 AM
#1885
“A linear increase in the response of patients Ortiz 06/29/2022 08:53:56 AM
Post Subject